Jagsonpal Pharma Peer Comparison

NSE: JAGSNPHARM | BSE: 507789

₹242.29

₹-1.68 (-0.69%)

As on 25-Sep-2026IST

Market cap

₹1,601 Cr

Revenue (TTM)

₹294 Cr

P/E Ratio

35.2

P/B Ratio

Div. Yield

2.3 %

Edit

	Jagsonpal Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	1,601	21,555	19,802	18,323	17,490
Revenue (₹ Cr)	294	2,287	1,682	2,570	3,230
Net Profit (₹ Cr)	45.48	678.07	273.51	735.15	666.92
Net Margin (%)	14.87	28.10	16.19	26.88	20.60
RoE (%)	17.79	19.73	11.15	19.16	18.75
Price to Earnings	35.22	32.40	66.60	24.92	27.16
Price-To-Book	6.95	5.87	7.37	4.16	4.34

Income Statement (₹ Cr)

	Jagsonpal Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Operating Revenue	293.85	2,287.33	1,682.47	2,569.77	3,229.67
Total Income	305.85	2,413.29	1,689.83	2,735.39	3,237.12
Total Expenditure	232.74	1,490.75	1,203.91	1,628.14	2,090.06
EBITDA	61.10	796.58	478.55	941.63	1,139.61
Depreciation	9.23	78.10	126.01	57.58	281.06
EBIT	51.87	718.48	352.55	884.05	858.55
Interest	1.03	0.88	52.11	7.69	190.64
Other Income	12.00	125.96	7.37	165.62	7.45
Exceptional Items	-2.08	0.00	12.16	-49.16	-17.24
Profit before Tax	60.77	843.56	319.96	992.82	658.12
Provision for Tax	15.29	165.49	46.45	257.67	-8.80
Profit after Tax	45.48	678.07	273.51	735.15	666.92

	Jagsonpal Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Shareholder's Funds	276.17	3,586.42	2,591.20	4,202.90	3,902.67
Minority Interest	0.00	-12.71	0.00	0.00	-21.81
Non-Current Liabilities	12.21	28.74	266.35	91.50	1,392.75
Current Liabilities	28.30	385.94	848.06	627.48	2,077.10
Total Liabilities	329.30	4,037.51	3,705.61	4,921.88	7,246.72

	Jagsonpal Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Non-Current Assets	78.53	1,291.22	2,525.44	770.28	5,617.77
Current Assets	143.09	2,585.66	1,109.77	3,803.22	1,539.85
Total Assets	329.30	4,037.51	3,705.61	4,921.88	7,246.72
Total Debt*	0.00	0.57	657.97	2.50	2,309.68
Net Current Assets	114.79	2,199.72	261.71	3,175.74	-537.25
Contingent Liabilities	22.34	17.53	160.01	370.49	51.57

	Jagsonpal Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Cash From Operating Activities	46.81	523.24	342.18	967.57	537.99
Cash Flow from Investing Activities	-35.65	-582.30	-325.92	-561.67	-369.46
Cash from Financing Activities	-12.15	-46.46	13.62	-798.31	-313.53
Net Cash Inflow / Outflow	-0.99	-105.52	29.88	-392.41	-145.00

	Jagsonpal Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
ROCE (%)	22.69	24.97	11.43	23.39	14.47
ROE (%)	17.79	19.73	11.15	19.16	18.75
ROA (%)	15.29	18.69	7.80	14.95	9.26
EBIT Margin (%)	17.65	31.41	20.95	34.40	26.58
Net Margin (%)	14.87	28.10	16.19	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Jagsonpal Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Revenue Growth (%)	3.87	15.01	27.91	10.69	9.59
EBIT Growth (%)	13.66	18.45	58.32	24.14	16.84
Net Profit Growth (%)	-25.24	19.61	149.56	-9.09	62.68
EPS Growth (%)	-20.48	17.73	-3.57	14.40	67.41
Book Value Growth (%)	17.30	26.75	9.67	-0.34	36.71

	Jagsonpal Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Price / Earnings	34.33	32.40	70.65	23.75	26.48
Price / Book Value	6.95	5.87	7.37	4.16	4.34
Dividend Yield (%)	2.27	0.28	0.06	1.87	0.00
EV/EBITDA	24.47	25.80	42.66	16.16	17.32
Market Cap (₹ Cr)	1,234.49	11,439.22	6,819.66	21,592.90	17,980.08

	Jagsonpal Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.00	0.07	0.00	0.24
Short term debt to equity ratio	--	0.00	0.16	0.00	0.12
Current Ratio	5.06	6.70	1.31	6.06	0.74
Quick Ratio	4.54	5.59	0.88	5.31	0.53
Interest Coverage	60.28	959.59	7.14	130.11	4.45

	Jagsonpal Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debtors to sales (%)	5.85	36.10	30.84	7.07	21.07
Asset Turnover	0.99	0.63	0.48	0.52	0.45
Receivable days	18.20	121.68	113.81	26.06	63.88
Inventory Days	17.89	63.83	84.76	65.95	43.27
Payable days	37.27	108.28	101.94	81.01	151.85
Cash Conversion Cycle	-1.18	77.23	96.62	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.